Investor Backing & Capital Strength:
Raised a $372 million Series D on June 26, 2024 with strategic participation from Sanofi, bringing total financing to roughly $600M+. This level of capital is described as supporting headcount expansion, pipeline acquisitions, and platform build‑out.
Strategic Partnerships:
Entered a first‑of‑its‑kind AI collaboration with Sanofi and OpenAI in May 2024, later highlighted by Sanofi in its filings. Additional Sanofi-linked licensing activity signals commercial traction and scale ambitions.
Product Line Growth:
Created Bleecker Bio and signed a December 2025 deal to develop Lynk Pharma’s TYK2 inhibitor (milestones up to $605M) with a Phase 1 start targeted for H1 2026. Disclosed programs, including at least one in Phase 3, indicate an expanding internal portfolio.
